Pulse Biosciences, Inc. (PLSE)
NASDAQ: PLSE · Real-Time Price · USD
21.59
+1.96 (9.98%)
At close: Mar 31, 2026, 4:00 PM EDT
21.59
0.00 (0.00%)
After-hours: Mar 31, 2026, 4:15 PM EDT
Pulse Biosciences Revenue
In the year 2025, Pulse Biosciences had annual revenue of $350.00K. Pulse Biosciences had revenue of $264.00K in the quarter ending December 31, 2025.
Revenue (ttm)
$350.00K
Revenue Growth
n/a
P/S Ratio
4,133.74
Revenue / Employee
$3,017
Employees
116
Market Cap
1.46B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 350.00K | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 700.00K | -718.00K | -50.63% |
| Dec 31, 2021 | 1.42M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| DENTSPLY SIRONA | 3.68B |
| ICU Medical | 2.23B |
| Embecta | 1.08B |
| Warby Parker | 871.91M |
| Azenta | 595.03M |
| AtriCure | 534.53M |
| LeMaitre Vascular | 249.60M |
| STAAR Surgical Company | 239.44M |
PLSE News
- 14 days ago - Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical Data - Business Wire
- 19 days ago - Pulse Biosciences, Inc. Announces First Enrollments in Feasibility Study for the Treatment of Malignant Thyroid Tumors with nPulse™ Technology - Business Wire
- 22 days ago - Pulse Biosciences Announces Clinical Data From nPulse™ Vybrance™ System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation - Business Wire
- 26 days ago - Pulse Biosciences to Present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference - Business Wire
- 27 days ago - Pulse Biosciences' nPulse™ Vybrance™ System to be Featured in Multiple Presentations at the North American Society for Interventional Thyroidology Meeting - Business Wire
- 5 weeks ago - Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 5 weeks ago - Pulse Biosciences to Present at the 46th Annual TD Cowen Healthcare Conference - Business Wire
- 5 weeks ago - Pulse Biosciences, Inc. (PLSE) Q4 2025 Earnings Call Transcript - Seeking Alpha